We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Inpharmatica Announces ISO 9001 Certification for its ADME Business

Inpharmatica Announces ISO 9001 Certification for its ADME Business

Inpharmatica Announces ISO 9001 Certification for its ADME Business

Inpharmatica Announces ISO 9001 Certification for its ADME Business

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Inpharmatica Announces ISO 9001 Certification for its ADME Business"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Inpharmatica Ltd. has announced the award of ISO 9001:2000 quality certification for its comprehensive ADME business, Admensa™.

The internationally accepted ISO 9001 Certification recognises Inpharmatica's commitment to a quality of service and customer care within its Admensa division.

The high level of customer care and service is bringing Inpharmatica an expanding list of international companies who have chosen to work with Inpharmatica to address their ADME needs.

40 customers have signed up to use Admensa, including recent additions Ark Therapeutics Group PLC, KuDOS Pharmaceuticals LimitediQur Limited and Canbex Therapeutics Limited, a spin out from UCL's Wolfson Institute.

Admensa is designed to offer a combination of ADME optimisation expertise, proprietary in silico tools, laboratory services and consulting, to enable early selection of compounds with an optimal balance of drug like properties.

A module of Admensa, Admensa Interactive™, Inpharmatica's in silico optimisation platform for drug discovery scientists, has recently been enhanced to offer improved QSAR ADME models, P450 metabolism models and unique compound prioritisation and selection methods within an intuitive, interactive design environment.

Admensa itself is an integral component of Inpharmatica's gene-to-candidate technology platform which integrates biology- and chemistry-based drug discovery activities.

The complete platform is designed to optimise target selection based on druggability, and enables identification of hits and selection of high quality leads and pre-clinical candidates, which are prioritised on the basis of good drug-like characteristics and clinical indication.

Commenting on the announcement, John Lisle, Inpharmatica's CEO, said, "This ISO 9001 certification means that Inpharmatica's customers can be even more confident that they will receive an excellent product and an excellent level of service and customer care."

"We have already seen high levels of customer satisfaction and the company is enjoying the extra sales that this brings."